KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $91.3 million.

  • CRISPR Therapeutics AG's Shares Outstanding (Weighted Average) rose 712.2% to $91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.3 million, marking a year-over-year increase of 712.2%. This contributed to the annual value of $84.4 million for FY2024, which is 648.59% up from last year.
  • CRISPR Therapeutics AG's Shares Outstanding (Weighted Average) amounted to $91.3 million in Q3 2025, which was up 712.2% from $87.1 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's Shares Outstanding (Weighted Average)'s 5-year high stood at $91.3 million during Q3 2025, with a 5-year trough of $75.0 million in Q1 2021.
  • Over the past 5 years, CRISPR Therapeutics AG's median Shares Outstanding (Weighted Average) value was $79.3 million (recorded in 2023), while the average stood at $81.4 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Shares Outstanding (Weighted Average) surged by 2326.71% in 2021 and then skyrocketed by 178.49% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Shares Outstanding (Weighted Average) (Quarter) stood at $75.0 million in 2021, then rose by 3.65% to $77.7 million in 2022, then grew by 1.9% to $79.2 million in 2023, then rose by 6.49% to $84.4 million in 2024, then grew by 8.23% to $91.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $91.3 million for Q3 2025, versus $87.1 million for Q2 2025 and $85.9 million for Q1 2025.